A Group of Hypermethylated miRNA Genes in Breast Cancer and Their Diagnostic Potential


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

miRNA genes play an important role in cancer pathogenesis, while they may be suppressed by hypermethylation. Here, we assess the diagnostic potential of a group of hypermethylated miRNA genes (MIR-124-1, MIR-124-3, MIR-125B-1, MIR-127, MIR-132, MIR-193a, and MIR-34b/c) in a representative set of 70 breast cancer samples and 17 breast tissue samples from deceased donors with no malignancies. For these seven genes, the methylation status is determined using the methylation-specific PCR. Methylation reached 26–76% in tumor specimens, 1‒27% in paired considered normal breast tissues, and 0–18% in breast tissue from deceased donors. By quantitative RT-PCR, reduced expression levels of the investigated miRNAs are detected, with a negative correlation of expression levels with gene hypermethylation. Combinations of three or four hypermethylation biomarkers, namely, MIR-124-1, MIR-125B-1, MIR-127, and MIR-34b/c are found suitable for breast cancer diagnostics; with sensitivity (76‒93%), specificity (88‒100%), and AUC (0.88‒0.94). Notably, the MIR-127 gene was hypermethylated only in the tumor samples of patients with metastases, and, therefore, should be tested as a marker of breast cancer dissemination. These findings may lead to improvement in the management of breast cancer.

Sobre autores

E. Filippova

Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Rússia, Moscow, 125315

V. Loginov

Institute of General Pathology and Pathophysiology; Research Center of Medical Genetics

Email: eleonora10_45@mail.ru
Rússia, Moscow, 125315; Moscow, 115478

I. Pronina

Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Rússia, Moscow, 125315

D. Khodyrev

Federal Research Clinical Center of Specialized Types of Medical Care and Medical Technologies,
Federal Medico-Biological Agency of Russia

Email: eleonora10_45@mail.ru
Rússia, Moscow, 115682

A. Burdennyy

Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Rússia, Moscow, 125315

T. Kazubskaya

Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Rússia, Moscow, 115478

E. Braga

Institute of General Pathology and Pathophysiology; Research Center of Medical Genetics

Autor responsável pela correspondência
Email: eleonora10_45@mail.ru
Rússia, Moscow, 125315; Moscow, 115478

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Pleiades Publishing, Inc., 2019